BTIG Research Reiterates Buy Rating for SOPHiA GENETICS (NASDAQ:SOPH)

SOPHiA GENETICS (NASDAQ:SOPH)‘s stock had its “buy” rating reaffirmed by investment analysts at BTIG Research in a report issued on Monday,Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 63.93% from the company’s current price.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $7.50.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $4.88 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The firm has a market cap of $334.21 million, a price-to-earnings ratio of -9.38 and a beta of 0.98. The firm has a 50 day simple moving average of $4.98 and a 200-day simple moving average of $4.89. SOPHiA GENETICS has a one year low of $2.59 and a one year high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

Insider Activity at SOPHiA GENETICS

In related news, CEO Jurgi Camblong sold 43,129 shares of the company’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total transaction of $213,919.84. Following the sale, the chief executive officer directly owned 3,664,440 shares in the company, valued at approximately $18,175,622.40. This represents a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 207,359 shares of company stock worth $1,013,067 over the last three months. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC increased its holdings in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at $2,157,000. Royce & Associates LP acquired a new stake in SOPHiA GENETICS in the fourth quarter valued at $2,009,000. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the first quarter valued at $1,772,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.